Know Cancer

or
forgot password

Advanced Renal Cell Carcinoma, With Failure or Unsuitable on Prior Interferon-alpha or Interleukin-2 Based Therapy


N/A
18 Years
N/A
Open (Enrolling)
Both
Carcinoma, Renal Cell

Thank you

Trial Information

Advanced Renal Cell Carcinoma, With Failure or Unsuitable on Prior Interferon-alpha or Interleukin-2 Based Therapy


Inclusion Criteria:



- Patients with diagnosis of advanced Renal Cell Carcinoma (RCC) and decision taken by
the investigator to prescribe Nexavar® under Taiwan reimbursement guideline

- Patients must have a life expectancy of at least 8 weeks

Exclusion Criteria:

- Exclusion criteria must follow the approved local product information.

- Patients were lost to follow-up if no follow-up visit and no final assessment of
Nexavar® was documented.

Type of Study:

Observational

Study Design:

Observational Model: Cohort, Time Perspective: Prospective

Outcome Measure:

Evaluation of Safety and Efficacy of treatments and average doses that are used for patients with Renal Cell Carcinoma (collection of number of adverse events)

Outcome Time Frame:

After one year

Safety Issue:

No

Principal Investigator

Bayer Study Director

Investigator Role:

Study Director

Investigator Affiliation:

Bayer

Authority:

Taiwan: Institutional Review Board

Study ID:

15242

NCT ID:

NCT01195649

Start Date:

December 2010

Completion Date:

March 2015

Related Keywords:

  • Carcinoma, Renal Cell
  • Carcinoma
  • Carcinoma, Renal Cell

Name

Location